PMV Pharmaceuticals Statistics
Total Valuation
PMVP has a market cap or net worth of $72.79 million. The enterprise value is -$45.98 million.
Important Dates
The next estimated earnings date is Friday, May 8, 2026, before market open.
| Earnings Date | May 8, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PMVP has 53.33 million shares outstanding. The number of shares has increased by 1.87% in one year.
| Current Share Class | 53.33M |
| Shares Outstanding | 53.33M |
| Shares Change (YoY) | +1.87% |
| Shares Change (QoQ) | +0.39% |
| Owned by Insiders (%) | 3.37% |
| Owned by Institutions (%) | 51.99% |
| Float | 46.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.63 |
| P/TBV Ratio | 0.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.09, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.09 |
| Quick Ratio | 9.89 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -55.37% and return on invested capital (ROIC) is -38.10%.
| Return on Equity (ROE) | -55.37% |
| Return on Assets (ROA) | -35.00% |
| Return on Invested Capital (ROIC) | -38.10% |
| Return on Capital Employed (ROCE) | -81.99% |
| Weighted Average Cost of Capital (WACC) | 11.29% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.44M |
| Employee Count | 54 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.17M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +19.27% in the last 52 weeks. The beta is 1.31, so PMVP's price volatility has been higher than the market average.
| Beta (5Y) | 1.31 |
| 52-Week Price Change | +19.27% |
| 50-Day Moving Average | 1.30 |
| 200-Day Moving Average | 1.32 |
| Relative Strength Index (RSI) | 43.29 |
| Average Volume (20 Days) | 454,407 |
Short Selling Information
The latest short interest is 1.49 million, so 2.78% of the outstanding shares have been sold short.
| Short Interest | 1.49M |
| Short Previous Month | 1.23M |
| Short % of Shares Out | 2.78% |
| Short % of Float | 3.21% |
| Short Ratio (days to cover) | 1.25 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -86.21M |
| Pretax Income | -79.91M |
| Net Income | -77.74M |
| EBITDA | -86.07M |
| EBIT | -86.21M |
| Earnings Per Share (EPS) | -$1.48 |
Full Income StatementBalance Sheet
The company has $112.94 million in cash and $838,000 in debt, with a net cash position of $112.11 million or $2.10 per share.
| Cash & Cash Equivalents | 112.94M |
| Total Debt | 838,000 |
| Net Cash | 112.11M |
| Net Cash Per Share | $2.10 |
| Equity (Book Value) | 104.71M |
| Book Value Per Share | 1.96 |
| Working Capital | 103.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$73.58 million and capital expenditures -$29,000, giving a free cash flow of -$73.61 million.
| Operating Cash Flow | -73.58M |
| Capital Expenditures | -29,000 |
| Depreciation & Amortization | 133,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -73.61M |
| FCF Per Share | -$1.38 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
